Physician profile
Samuel Lev Moskowitz
NPI 1932336161
$4,508.33
in general payments reported to CMS, 2019-2025
35 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $742 · 2021: $760 · 2022: $789 · 2023: $434 · 2024: $538 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $704.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.77 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $397.22 | 2019-2022 | |
| Pfizer INC. | $324.28 | 2019-2025 | |
| Amgen INC. | $293.63 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $276.58 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $265.27 | 2019-2024 | |
| Abbvie INC. | $224.29 | 2019-2025 | |
| Corcept Therapeutics | $210.95 | 2024-2025 | Korlym |
| Abbott Laboratories | $204.51 | 2022-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $204.30 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $129.27 | 2019-2024 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $108.22 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.25 | 2020-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $83.50 | 2019-2023 | Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.54 | 2021 | |
| Mylan Specialty L.P. | $50.39 | 2020-2024 | Yupelri |
| Endo USA, INC. | $49.70 | 2025 | Xiaflex, Aveed |
| Astellas Pharma US INC | $48.21 | 2019 | |
| Phathom Pharmaceuticals, INC. | $39.05 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $36.58 | 2019 | |
| Esperion Therapeutics, INC. | $31.41 | 2020-2021 | |
| Glaxosmithkline, LLC. | $23.56 | 2020 | |
| Eisai INC. | $21.28 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.28 | 2022 | |
| Kyowa Kirin, INC. | $19.07 | 2023 | Crysvita |
| Smith+Nephew, INC. | $18.63 | 2022 | |
| Grifols USA, LLC | $18.10 | 2019 | |
| Dexcom, INC. | $17.54 | 2024 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $16.62 | 2022 | |
| Pharming Healthcare, INC. | $16.20 | 2024 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $14.29 | 2020 | |
| Amarin Pharma, INC. | $12.31 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.84 | 2021 | |
| Adlon Therapeutics L.P. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Moskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.